Financial Survey: Enliven Therapeutics (NASDAQ:ELVN) vs. Processa Pharmaceuticals (NASDAQ:PCSA)

Processa Pharmaceuticals (NASDAQ:PCSA) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Profitability

This table compares Processa Pharmaceuticals and Enliven Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Processa Pharmaceuticals	N/A	-141.42%	-122.25%
Enliven Therapeutics	N/A	-26.56%	-25.18%

Institutional and Insider Ownership

91.9% of Processa Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 22.2% of Processa Pharmaceuticals shares are owned by company insiders. Comparatively, 45.8% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Processa Pharmaceuticals and Enliven Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Processa Pharmaceuticals	N/A	N/A	-$11.12 million	($7.44)	-0.29
Enliven Therapeutics	N/A	N/A	-$71.58 million	($2.19)	-7.84

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Processa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Processa Pharmaceuticals and Enliven Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Processa Pharmaceuticals	0	1	2	0	2.67
Enliven Therapeutics	0	0	1	0	3.00

Processa Pharmaceuticals currently has a consensus target price of $8.00, indicating a potential upside of 272.09%. Enliven Therapeutics has a consensus target price of $34.00, indicating a potential upside of 97.90%. Given Processa Pharmaceuticals’ higher possible upside, equities analysts clearly believe Processa Pharmaceuticals is more favorable than Enliven Therapeutics.

Risk and Volatility

Processa Pharmaceuticals has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Summary

Enliven Therapeutics beats Processa Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.